武汉大学人民医院湖北省人民医院

院内导航

陈永顺肿瘤
科主任，教授，主任医师，博士生导师

A+ A-

导师介绍

姓名	陈永顺
出生年月	1976年7月
单位	武汉大学人民医院肿瘤中心
所属学科	临床医学-肿瘤学
职务、职称及头衔	科主任，教授，主任医师，博士生导师
E-mail	yongshun2007@163.com
联系方式	027-88041911转81341或153-2712-2084
研究方向	1.消化系统肿瘤的综合治疗 2.肿瘤精准放疗的基础和临床
个人简介	专业方向为消化系统肿瘤的放射治疗和靶向、免疫治疗，晚期食管癌精准放射治疗体系创建者。主持国家自然科学基金及国家级、省部级课题8项，发表论文50余篇，以第一/通讯作者在JNO, Chemical Sci, Clin Transl Med, Int J Surg,放疗红皮、绿皮等发表文章50余篇，多个研究成果在ASCO, ASCO-GI, ASTRO, ESMO, OESO, CSCO, CSTRO等国际、国内会议上口头报告/壁报交流。
学术任职与荣誉	中国抗癌协会肿瘤微生态专家协作组副组长中华医学会肿瘤学分会食管癌专家组委员中华医学会放射肿瘤治疗学分会第八届全国青年委员中国生物医学工程学会肿瘤分子靶向治疗专委会委员湖北省临床肿瘤学会精准放疗专家委员会主任委员湖北省医学会放射肿瘤治疗学会副主任委员湖北省抗癌协会胰腺癌专业委员会副主任委员湖北省临床肿瘤学会食管癌专家组副主任委员
教育履历	1995.09-2000.06河南医科大学临床医学专业本科生获学士学位 2003.09-2006.06郑州大学医学院病理学与病理生理学硕士研究生获硕士学位 2007.09-2010.06四川大学华西临床医学院肿瘤学博士研究生获博士学位
工作履历	2000.08-2007.08 郑州人民医院肿瘤科住院医师、主治医师 2010.08-2016.08 郑州大学附属肿瘤医院副主任医师 2013.07-2014.05 澳洲Peter MacCallum Cancer Cente博士后 2016.09-至今武汉大学人民医院肿瘤中心教授、主任医师
成果获奖	1.《西妥昔单抗联合同步放化疗治疗局部进展期食管癌》获2015年医学新技术引进二等奖 2.《靶向及智能放疗质控体系创新与应用》获2020年湖北省科技进步二等奖
代表性论著	1. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous carcinoma of the esophagus: a propensity score-matched analysis. Radiotherapy and Oncology 2018; 129: 154–160. 2. Enhancing the Photodynamic Therapy Efficacy of Black Phosphorus Nanosheets by Covalently Grafting Fullerene C60. Chemical Science 2020, 11, 11435-11442. 3. Buffer wards for the control of COVID-19 transmission in hospitals. Clinical & Translational Medicine 2020;10(7): e223. 4. Dysfunction of apoptosis and autophagy correlates with local recurrence in esophageal squamous cell carcinoma after definitive chemoradiation. Cancer Cell International 2021; 21: 466. 5. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiotherapy and Oncology 2021; 164: 236-244 6. Preoperative chemotherapy for limited-stage small cell carcinoma of the esophagus. The Annals of Thoracic Surgery 2022; 114(4): 1220-1228. 7. Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. Biochem Pharmacol. 2022 Aug; 202:115153. doi: 10.1016/j.bcp.2022.115153. 8. Evaluation of Concurrent Chemoradiotherapy in Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. JAMA Network Open 2022; 5(12):e2244619 9. Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer. Biomed J. 2023 Feb; 46(1): 110-121. doi: 10.1016/j.bj.2022.01.007. 10. Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer. Int Immunopharmacol. 2023 Jun 6;121:110350. doi: 10.1016/j.intimp.2023.110350. 11. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial. Radiother Oncol. 2023 Jul;184:109679. doi: 10.1016/j.radonc.2023.109679. 12. Efficacy of endoscopic therapy for T1b esophageal cancer and construction of prognosis prediction model: a retrospective cohort study. Int J Surg. 2023 Jun 1;109(6):1708-1719.

Name	Yongshun Chen
Date of birth	July，1976
Department	Oncology Department，Renmin Hospital of Wuhan University
Title	Director, Professor, Doctoral tutor
Email	yongshun2007@163.com
TEL	027-88041911-81341 or 153-2712-2084
Research Direction	1. Integrative therapy of digestive oncology 2. Radiosensitization and cancer therapy
Personal Profile	He is mainly engaged in the diagnosis and treatment of digestive oncology, and has been awarded 2 items for the National Natural Science Foundation, several items from the provincial science and Technology Department. There are more than 50 SCI articles published in JAMA Network Open, International Journal of Surgery, Chemical Science, Clin Transl Med, Radiotherapy & Oncology, Cancer Science and Diseases of the Esophagus.
Selected Publications	1. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous carcinoma of the esophagus: a propensity score-matched analysis. Radiotherapy and Oncology 2018; 129: 154–160. 2. Enhancing the Photodynamic Therapy Efficacy of Black Phosphorus Nanosheets by Covalently Grafting Fullerene C60. Chemical Science 2020, 11, 11435-11442. 3. Buffer wards for the control of COVID-19 transmission in hospitals. Clinical & Translational Medicine 2020;10(7): e223. 4. Dysfunction of apoptosis and autophagy correlates with local recurrence in esophageal squamous cell carcinoma after definitive chemoradiation. Cancer Cell International 2021; 21: 466. 5. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiotherapy and Oncology 2021; 164: 236-244 6. Preoperative chemotherapy for limited-stage small cell carcinoma of the esophagus. The Annals of Thoracic Surgery 2022; 114(4): 1220-1228. 7. Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. Biochem Pharmacol. 2022 Aug; 202:115153. doi: 10.1016/j.bcp.2022.115153. 8. Evaluation of Concurrent Chemoradiotherapy in Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. JAMA Network Open 2022; 5(12):e2244619 9. Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer. Biomed J. 2023 Feb; 46(1): 110-121. doi: 10.1016/j.bj.2022.01.007. 10. Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer. Int Immunopharmacol. 2023 Jun 6;121:110350. doi: 10.1016/j.intimp.2023.110350. 11. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial. Radiother Oncol. 2023 Jul;184:109679. doi: 10.1016/j.radonc.2023.109679. 12. Efficacy of endoscopic therapy for T1b esophageal cancer and construction of prognosis prediction model: a retrospective cohort study. Int J Surg. 2023 Jun 1;109(6):1708-1719.